<DOC>
	<DOCNO>NCT00701935</DOCNO>
	<brief_summary>A multicenter , randomize , double-blind , placebo-controlled trial ass effect twice-daily subcutaneous injection exenatide versus treatment match placebo injection abdominal visceral fat content .</brief_summary>
	<brief_title>Effect Exenatide Abdominal Fat Distribution Patients With Type 2 Diabetes Pretreated With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients 18 85 year age , inclusive . Patients type 2 diabetes Patients treat metformin , stable dose least 3 month prior Visit 1 Patients HbA1c 7.0 % 8.9 % , inclusive . Patients body mass index &gt; 27 kg/m2 &lt; 40 kg/m2 meet local CT scan body weight requirement . For South Asian , Japanese , Chinese patient , body mass index &gt; =25 kg/m2 acceptable low limit . Patients history stable body weight ( vary &gt; 2 kg 3 month prior Visit 1 ) . Medications treatment high blood pressure stable respect treatment regimen 4 week prior Visit 1 . Stable regimen lipidlowering agent 6 week prior Visit 1 . Have receive treatment last 30 day drug receive regulatory approval indication time study entry . Have active untreated malignancy , remission clinically significant malignancy ( basal cell squamous cell skin cancer , situ carcinoma cervix , situ prostate cancer ) less 5 year . Have history renal transplantation , currently receive renal dialysis . Have clinically significant history cardiac disease presence active cardiac disease within 1 year prior Visit 1 , include myocardial infarction , clinically significant arrhythmia , unstable angina , moderate severe congestive heart failure , coronary artery bypass surgery , angioplasty ; expect require coronary artery bypass surgery angioplasty course study . Have know hemoglobinopathy clinically significant , chronic anemia . Known likely become transfusion dependent study . Have active , symptomatic proliferative retinopathy . Are receive chronic treatment gastrointestinal disease drug directly affect gastrointestinal motility . ( i.e . metoclopramide , cisapride , chronic use macrolide antibiotic ) Have severe gastrointestinal disease , include gastroparesis . Are receive chronic ( lasting longer 2 week ) systemic glucocorticoid therapy ( exclude topical inhale preparation ) receive therapy within 2 month immediately prior Visit 1 . Have take exenatide , liraglutide GLP1 receptor agonist past 6 month , either clinical study commercially available medication . Patients know allergy exenatide exclude . Have use prescription counter drug promote weight loss within 3 month prior Visit 1 , intend use drug study . ( Examples : Xenical [ orlistat ] , Meridia [ sibutramine ] , Acutrim [ phenylpropanolamine ] , Acomplia [ rimonabant ] ) . Have participate structured weight loss program within 3 month prior Visit 1 , intend participate plan study . Have treat longer 2 week follow excluded medication within 3 month prior Visit 1 : Insulin ; Thiazolidinediones ; Alphaglucosidase inhibitor ; Sulfonylureas ; Oral DPPIV inhibitor ; Meglitinides . Are take warfarin , coumarol derivative .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>